COPD

The 25-mg brensocatib group showed statistically significant changes in FEV1 decline as well as pulmonary exacerbations.

Participants in the cytisinicline group also had a significantly greater reduction in smoking urges.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

This interview in the latest issue of The Respiratory Report features William Zhang, MD, discussing AM iron accumulation, which may contribute to the well-known phenomenon of AM dysfunction in COPD6.

This interview in the latest issue of The Respiratory Report features Peter Miller, MD, PhD, discussing the potential role of CH in developing COPD.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

By year 5, COPD exacerbations occurred in 81.3% of the PPV23 group and 23.6% of the PCV13 group.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.

Panelists discuss how chronic obstructive pulmonary disease (COPD) management is evolving with personalized therapies, nonpharmacological care, and advanced treatments. Early diagnosis, adherence, and innovation offer hope for improved outcomes and quality of life.

Panelists discuss how key nonpharmacological interventions include vaccinations to prevent infections, pulmonary rehabilitation to improve function, and lung cancer screening for high-risk patients to enable early detection.

Panelists discuss how individualized chronic obstructive pulmonary disease (COPD) maintenance therapy considers symptom severity, exacerbation risk, and eosinophil levels. Dupilumab and ensifentrine require adherence to prescribed dosing for efficacy and safety.

Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.

Approved under the name Dupixent in September 2024, the biologic is the first of its kind approved for COPD.

Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.

Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction.

Panelists discuss how monitoring blood eosinophil counts is crucial for assessing inflammation in asthma and chronic obstructive pulmonary disease (COPD). It guides treatment decisions by identifying patients who may benefit from corticosteroids or biologics.

Panelists discuss how the coexistence of heart disease and chronic obstructive pulmonary disease (COPD) requires careful management as these conditions significantly impact each other. In stable COPD, cardiovascular complications are a leading cause of mortality, whereas acute exacerbations can worsen heart function. Key treatable traits in COPD-associated pulmonary hypertension include hypoxemia, inflammation, and right ventricular dysfunction. Management focuses on optimizing respiratory and cardiac function through appropriate medication selection, oxygen therapy when indicated, and careful monitoring of both conditions to prevent deterioration.

However, subgroup analyses may reveal a more pronounced effect in people with severe COPD.

Panelists discuss how dysbiosis of the lung microbiome can exacerbate chronic obstructive pulmonary disease (COPD) through increased inflammation and altered immune responses. In contrast, chest CT imaging is indicated for patients with severe COPD, suspected comorbidities, surgical planning, or unexplained symptoms despite standard treatment. These factors highlight the complexity of COPD management.

Panelists discuss the initial thought that postbronchodilator spirometry would help differentiate chronic obstructive pulmonary disease (COPD) from asthma. However, postbronchodilator spirometry adds time and effort, as well as exposing a patient to short-term medication that may have adverse effects. Guidelines favor a fixed ratio of forced expiratory volume in the first second to forced vital capacity (FEV1/FVC; < 0.7) because of the ratio’s simplicity and is independent of other reference values.

Meteorological conditions’ effect on exacerbations were likely mediated by particulate matter.